Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.

Moderna released interim data from the expansion cohort of an ongoing Phase I trial of the company’s mRNA personalized cancer vaccine mRNA-4157, which is being tested in combination with Merck’s checkpoint inhibitor Keytruda (pembrolizumab).

Three biopharma companies recently shuttered their clinical programs after either their drug compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints.

A small but key UK study found that “cellular immunity” to the pandemic SARS-CoV-2 virus is present after six months in people who had mild or asymptomatic Covid-19, suggesting they might have some level of protection for at least that time.

Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community.

Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.

A new form of treatment known as CAR-T cell therapy has been making waves in the field of oncology, and clinical trials have begun for patients with Malignant Pleural Mesothelioma (MPM).

A lower supply of a certain type of immune cell in older people that is critical to fighting foreign invaders may help explain their vulnerability to severe Covid-19, scientists say. An antiseptic nasal spray containing povidone-iodine may help curb transmission of the new coronavirus, preliminary research suggests.

AstraZeneca resumed the company’s Covid-19 vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

To develop an effective treatment or vaccine for Covid-19, scientists must understand how the immune system is impacted during the disease.